Claims for Patent: 4,918,105

Summary for Patent: 4,918,105

Title:	Novel compounds with collagenase-inhibiting activity, a process for their preparation and pharmaceutical compositions in which these compounds are present
Abstract:	The present invention relates to a novel family of chemical compounds possessing a pharmacological activity, in particular a collagenase-inhibiting activity, a process for the production of these compounds and pharmaceutical compositions in which they are present. According to the invention, these compounds correspond to the general formula: ##STR1## in which: W represents an amino acid residue selected from the group comprising valine, lysine, norleucine and methionine, and Z represents an amino radical or an alkylamino radical of which the alkyl part, which contains 1 or 2 carbon atoms, is substituted by a phenyl or trifluorophenyl radical, and also include their diastereoisomers and their addition salts with pharmaceutically acceptable acids. The invention is applicable especially in the pharmaceutical industry.
Inventor(s):	Cartwright; Terence (Saint Epain, FR), Bouboutou-Tello; Romaine (Arceuil, FR), Lelievre; Yves (Tours, FR), Fournier-Zaluski; Marie-Claude (Paris, FR)
Assignee:	SA Laboratoire Roger Bellon (Neuilly-Sur-Seine, FR)
Application Number:	07/141,072
Patent Claims:	1. Compounds with collagenase-inhibiting activity, corresponding to the general formula: ##STR67## in which: W represents an amino acid residue selected from the group consisting of valine, lysine, norleucine and methionine, and Z represents an amino radical or an alkylamino radical of which the alkyl part, which contains 1 or 2 carbon atoms, is substituted by a phenyl or trifluorophenyl radical, and also their diastereoisomers and their addition salts with pharmaceutically acceptable acids. 2. Compounds as claimed in claim 1 which correspond to formula I in which W represents an L-valyl group. 3. Compounds as claimed in claim 1, selected from the group comprising the following: N.alpha.-(N-hydroxy-2-isobutylsuccinamoyl)-L-valinamide, N-benzyl-N.alpha.-(N-hydroxy-2-isobutylsuccinamoyl)-L-valinamide N-(4-trifluoromethylbenzyl)-N.alpha.-(N-hydroxy-2-isobutylsuccinamoyl)-L-va linamide N-phenethyl-N.alpha.-(N-hydroxy-2-isobutylsuccinamoyl)-L-valinamide N-benzyl-N.alpha.-(N-hydroxy-2-isobutylsuccinamoyl)-L-norleucine and N-benzyl-N.alpha.-(N-hydroxy-2-isobutylsuccinamoyl)-L-lysinamide N-benzyl-N.alpha.-(N-hydroxy-2-isobutylsuccinamoyl)-L-methioninamide. 4. A pharmaceutical composition which contains at least a compound as claimed in one of claims 1 or 3 as the active ingredient, in association with a pharmaceutically acceptable, non-toxic vehicle or excipient. 5. A pharmaceutical composition with collagenase-inhibiting activity, which contains at least a compound as claimed in one of claims 1 or 3 as the active ingredient, in association with a pharmaceutically acceptable, non-toxic vehicle or excipient. 6. A pharmaceutical composition according to claim 5, wherein the active ingredient is in the form of the most active isomer, as determined after separation of the distinct isomeric forms of the compound. 7. A pharmaceutical composition with collagenase inhibiting activity, which contains at least one compound as claimed in claim 2, as the active ingredient, in association with a pharmaceutically acceptable, non-toxic vehicle or excipient, wherein the active ingredient is in the form of the most active isomer, as determined after separation of the distinct isomeric forms of the compound, said active isomer being characterized in NMR by the chemical shift situated at or below 2 ppm and corresponding to the >CH.sub..beta. -- of the valine. 8. Method of treatment of diseases which involve excessive destruction of collagen by collagenase, wherein said method comprises administering a pharmaceutical composition according to claim 5. 9. Method of treatment of diseases which involve excessive destruction of collagen by collagenase, wherein said method comprises administering a pharmaceutical composition according to claim 6. 10. Compounds as claimed in claim 1, wherein Z represents an alkylamino radical of which the alkyl part, which contains 1 or 2 carbons, is substituted by a phenyl or trifluorophenyl radical.

Details for Patent 4,918,105

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2007-04-17